---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-218828"
form_type: "8-K"
ticker: "CNTA"
cik: "0001847903"
company_name: "Centessa Pharmaceuticals plc"
filed_at: "2024-09-13T23:59:59+00:00"
generated_at: "2026-05-31T05:01:22.783054+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Centessa prices upsized $225M ADS offering at $14.75/ADS; net proceeds ~$211M

## Summary
- Upsized offering: 15,254,237 ADSs at $14.75/ADS, gross proceeds ~$225M.
- Underwriters have 30-day option for additional 2,288,135 ADSs.
- Net proceeds ~$211M (or ~$242.7M with full overallotment) to fund product development and corporate.
- Company expects existing cash plus net proceeds to fund operations into mid-2027.
- Offering expected to close Sept 16, 2024; Goldman Sachs and Leerink Partners lead underwriters.

## SEC filing metadata
- accession: 0001193125-24-218828
- form_type: 8-K
- ticker: CNTA
- cik: 0001847903
- company_name: Centessa Pharmaceuticals plc
- filed_at: 2024-09-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1847903/000119312524218828/0001193125-24-218828-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1847903/000119312524218828/d878816d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-218828
- JSON: https://secwatch.observer/filing/0001193125-24-218828.json
- Plain text: https://secwatch.observer/filing/0001193125-24-218828.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.